p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis.
The importance of p38 MAPK inhibitors as new drug for rheumatoid arthritis is reflected by the large number of compounds that has been developed over the last years. In this review new insights such as non-stressful activation of p38 MAPK, and the role of p38 MAPK in regulation of NF-kappaB recruitment are also discussed.
Westra
J
J
Department of Rheumatology, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands. j.westra@med.umcg.nl
Limburg
P C
PC
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D004789:Enzyme Activation; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D048051:p38 Mitogen-Activated Protein Kinases